Conference Reports for NATAP

Back

EHDRW 6th European HIV Drug Resistance Workshop Budapest, Hungary March 26-28, 2008     Complete slide or poster presentations for some 6th European Resistance Workshop (Budapest, 26-28 March 2008) reports are available via the home page of the meeting organizer, Virology Education   http://www.virology-education.com   http://www.hivpresentation.com/   Efficacy of DRV/r in the randomised, controlled, Phase III ARTEMIS trial in treatment-naive, HIV-1-infected patients is independent of HIV-1 subtype (04/07/08)   One in 10 Genotyped Britons Started Therapy With Resistant HIV - Written by Mark Mascolini - (04/02/08)   Resistance Measured by Clinical Cutoff Drops Sharply From 1998 to 2007 - Written by Mark Mascolini - (04/02/08)   Identification of mutations predictive of a diminished response to darunavir/ritonavir (refined profile): analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and DUET-2 (04/02/08)   Prevalence of Darunavir-Linked Mutations Stays Low After Licensing - Written by Mark Mascolini - (03/31/08)   Update on the prevalence of the 2007 darunavir resistance-associated mutations in samples received for routine clinical resistance testing - (03/31/08)   Has Pretreatment Genotyping Improved Therapy? Answers From Germany - Written by Mark Mascolini - (03/31/08)   Combined protease inhibitor (PI) and NNRTI resistance analysis of the pooled DUET trial: towards a regimen-based resistance interpretation (03/31/08)   Virco Proposes Preliminary Biological Cutoffs for Integrase Inhibitors - Written by Mark Mascolini - (03/31/08)   More Major Mutations in Newly Diagnosed, Untreated Italian Patients - Written by Mark Mascolini - (03/31/08)   Nevirapine and Slow Genotyping Raise Risk of Resistance to Etravirine - Written by Mark Mascolini - (03/28/08)   People With Subtype A or C May Respond More Rapidly to HAART - Written by Mark Mascolini - (03/28/08)   "Historic" Resistance Profile Helps Predict PI and Overall Salvage Failure - Written by Mark Mascolini - (03/28/08)   Single Mutations at Raltegravir Failure Suggest Low Resistance Barrier - Written by Mark Mascolini - (03/28/08)   Background Drugs and Bad Adherence Explain Most Maraviroc Failures - Written by Mark Mascolini - (03/28/08)   Trofile Assay Usually Matches Cell Test in Figuring Coreceptor Use - Written by Mark Mascolini - (03/28/08)   "Staggering" Did Not Ward Off NNRTI Resistance in SMART Drug Breaks - Written by Mark Mascolini - (03/27/08)   Steady Drop in Resistant Virus Rates at Virologic Failure in Italy - Written by Mark Mascolini - (03/27/08)   Transmitted AZT/d4T-Resistant Virus Persists Up 4 Years Without Treatment - Written by Mark Mascolini - (03/27/08)   Tibotec Refines List of Darunavir-Specific Mutations - Written by Mark Mascolini - (03/27/08)   Classic Nonnucleoside Mutations Emerge Upon Etravirine Failure - Written by Mark Mascolini - (03/27/08)   Up to Four 'Combined' Darunavir/Etravirine Mutations Needed for Sub-50-Copy Response. New Concept in Resistance: Combined Resistance to Multiple Drugs in Regimen - Written by Mark Mascolini - (03/27/08)